Active vaccination in patients with common variable immunodeficiency (CVID)
Abstract Active vaccination of CVID patients with standard vaccines has rarely been studied in depth although some patients have been shown to develop transient vaccine-specific immunity. We addressed the question whether these patients can be identified by functional classification of their B cell...
Gespeichert in:
| Veröffentlicht in: | Clinical Immunology 2007-09, Vol.124 (3), p.294-303 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 303 |
|---|---|
| container_issue | 3 |
| container_start_page | 294 |
| container_title | Clinical Immunology |
| container_volume | 124 |
| creator | Goldacker, S Draeger, R Warnatz, K Huzly, D Salzer, U Thiel, J Eibel, H Schlesier, M Peter, H.H |
| description | Abstract Active vaccination of CVID patients with standard vaccines has rarely been studied in depth although some patients have been shown to develop transient vaccine-specific immunity. We addressed the question whether these patients can be identified by functional classification of their B cell subsets in vitro . Twenty-one CVID patients receiving regular IgG substitution were immunized with anti-peptide and anti-polysaccharide vaccines. Humoral vaccination responses were compared to the numbers of circulating memory B cells, CD21low B cells and the capacity to produce antibodies in vitro. Our findings allow four conclusions: (1) positive vaccination responses are not contradictory to the diagnosis of CVID; they occurred against polypeptide vaccines in 23% and against polysaccharide antigens in 18% of all vaccinations. (2) Class-switched antibody responses occur preferentially in patients of CVID group II. (3) A normal percentage of IgM memory B cells is necessary but not sufficient for a vaccination response to polysaccharide antigens. (4) Active vaccination in addition to IgG replacement therapy should be performed in patients of CVID type II — especially in case of vaccines for which passive protection cannot be guaranteed. |
| doi_str_mv | 10.1016/j.clim.2007.04.011 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68172707</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1521661607011801</els_id><sourcerecordid>68172707</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-a8cd4f1e5b25d0201d09c820f63fba98dc9fc86bd1db7a4bedc250bfd19f5df73</originalsourceid><addsrcrecordid>eNqFkk2LFDEQhoMo7of-AQ_SFxc9TFvJdJJukIVl1tXFBQ9-XEO6kmDG7vSYdI_Mvze907DgQU8pwvNWiidFyAsKJQUq3m5L7HxfMgBZQlUCpY_IKeWMriSs-eOlFoKKE3KW0hYAOGPiKTmhUgCrZXVKPl3h6Pe22GtEH_Toh1D4UOxyZcOYit9-_FHg0Pf5fq-j121nC9_3UxiMdR4zhYfi9eb77fWbZ-SJ012yz5fznHy7ef9183F19_nD7ebqboWVhHGlazSVo5a3jBtgQA00WDNwYu1a3dQGG4e1aA01rdRVaw0yDq0ztHHcOLk-JxfHvrs4_JpsGlXvE9qu08EOU1KippJJ-D_IsibW8BlkRxDjkFK0Tu2i73U8KApqdq22anatZtcKKpVd59DLpfvU9tY8RBa5GXi1ADqh7lzUAX164BqomOAsc--OnM3S9t5Gle69WuOjxVGZwf97jsu_4hkJPr_40x5s2g5TDPk7FFWJKVBf5q2YlwJkTtdA138APAiyEg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20352957</pqid></control><display><type>article</type><title>Active vaccination in patients with common variable immunodeficiency (CVID)</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elsevier ScienceDirect Journals</source><source>Wiley Online Library Free Content</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>IngentaConnect Free/Open Access Journals</source><source>PubMed Central</source><creator>Goldacker, S ; Draeger, R ; Warnatz, K ; Huzly, D ; Salzer, U ; Thiel, J ; Eibel, H ; Schlesier, M ; Peter, H.H</creator><creatorcontrib>Goldacker, S ; Draeger, R ; Warnatz, K ; Huzly, D ; Salzer, U ; Thiel, J ; Eibel, H ; Schlesier, M ; Peter, H.H</creatorcontrib><description>Abstract Active vaccination of CVID patients with standard vaccines has rarely been studied in depth although some patients have been shown to develop transient vaccine-specific immunity. We addressed the question whether these patients can be identified by functional classification of their B cell subsets in vitro . Twenty-one CVID patients receiving regular IgG substitution were immunized with anti-peptide and anti-polysaccharide vaccines. Humoral vaccination responses were compared to the numbers of circulating memory B cells, CD21low B cells and the capacity to produce antibodies in vitro. Our findings allow four conclusions: (1) positive vaccination responses are not contradictory to the diagnosis of CVID; they occurred against polypeptide vaccines in 23% and against polysaccharide antigens in 18% of all vaccinations. (2) Class-switched antibody responses occur preferentially in patients of CVID group II. (3) A normal percentage of IgM memory B cells is necessary but not sufficient for a vaccination response to polysaccharide antigens. (4) Active vaccination in addition to IgG replacement therapy should be performed in patients of CVID type II — especially in case of vaccines for which passive protection cannot be guaranteed.</description><identifier>ISSN: 1521-6616</identifier><identifier>EISSN: 1521-7035</identifier><identifier>EISSN: 1365-2567</identifier><identifier>DOI: 10.1016/j.clim.2007.04.011</identifier><identifier>PMID: 17602874</identifier><identifier>CODEN: CLIIFY</identifier><language>eng</language><publisher>San Diego, CA: Elsevier Inc</publisher><subject>Adult ; Aged ; Allergy and Immunology ; Antibody Formation - immunology ; B-Lymphocytes - classification ; B-Lymphocytes - immunology ; Biological and medical sciences ; Common Variable Immunodeficiency - classification ; Common Variable Immunodeficiency - immunology ; Common Variable Immunodeficiency - therapy ; CVID ; Female ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Humans ; IgM memory B cells ; Immunoglobulin G - blood ; Immunoglobulin M - blood ; Immunologic Memory ; Lymphocyte Subsets - classification ; Lymphocyte Subsets - immunology ; Male ; Medical sciences ; Middle Aged ; Peptides - therapeutic use ; Pneumococcal polysaccharides ; Pneumococcal Vaccines - therapeutic use ; Polypeptides ; Polysaccharides - therapeutic use ; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis ; Streptococcus pneumoniae - immunology ; Vaccination</subject><ispartof>Clinical Immunology, 2007-09, Vol.124 (3), p.294-303</ispartof><rights>Elsevier Inc.</rights><rights>2007 Elsevier Inc.</rights><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-a8cd4f1e5b25d0201d09c820f63fba98dc9fc86bd1db7a4bedc250bfd19f5df73</citedby><cites>FETCH-LOGICAL-c470t-a8cd4f1e5b25d0201d09c820f63fba98dc9fc86bd1db7a4bedc250bfd19f5df73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1521661607011801$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19042652$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17602874$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Goldacker, S</creatorcontrib><creatorcontrib>Draeger, R</creatorcontrib><creatorcontrib>Warnatz, K</creatorcontrib><creatorcontrib>Huzly, D</creatorcontrib><creatorcontrib>Salzer, U</creatorcontrib><creatorcontrib>Thiel, J</creatorcontrib><creatorcontrib>Eibel, H</creatorcontrib><creatorcontrib>Schlesier, M</creatorcontrib><creatorcontrib>Peter, H.H</creatorcontrib><title>Active vaccination in patients with common variable immunodeficiency (CVID)</title><title>Clinical Immunology</title><addtitle>Clin Immunol</addtitle><description>Abstract Active vaccination of CVID patients with standard vaccines has rarely been studied in depth although some patients have been shown to develop transient vaccine-specific immunity. We addressed the question whether these patients can be identified by functional classification of their B cell subsets in vitro . Twenty-one CVID patients receiving regular IgG substitution were immunized with anti-peptide and anti-polysaccharide vaccines. Humoral vaccination responses were compared to the numbers of circulating memory B cells, CD21low B cells and the capacity to produce antibodies in vitro. Our findings allow four conclusions: (1) positive vaccination responses are not contradictory to the diagnosis of CVID; they occurred against polypeptide vaccines in 23% and against polysaccharide antigens in 18% of all vaccinations. (2) Class-switched antibody responses occur preferentially in patients of CVID group II. (3) A normal percentage of IgM memory B cells is necessary but not sufficient for a vaccination response to polysaccharide antigens. (4) Active vaccination in addition to IgG replacement therapy should be performed in patients of CVID type II — especially in case of vaccines for which passive protection cannot be guaranteed.</description><subject>Adult</subject><subject>Aged</subject><subject>Allergy and Immunology</subject><subject>Antibody Formation - immunology</subject><subject>B-Lymphocytes - classification</subject><subject>B-Lymphocytes - immunology</subject><subject>Biological and medical sciences</subject><subject>Common Variable Immunodeficiency - classification</subject><subject>Common Variable Immunodeficiency - immunology</subject><subject>Common Variable Immunodeficiency - therapy</subject><subject>CVID</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Humans</subject><subject>IgM memory B cells</subject><subject>Immunoglobulin G - blood</subject><subject>Immunoglobulin M - blood</subject><subject>Immunologic Memory</subject><subject>Lymphocyte Subsets - classification</subject><subject>Lymphocyte Subsets - immunology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Peptides - therapeutic use</subject><subject>Pneumococcal polysaccharides</subject><subject>Pneumococcal Vaccines - therapeutic use</subject><subject>Polypeptides</subject><subject>Polysaccharides - therapeutic use</subject><subject>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</subject><subject>Streptococcus pneumoniae - immunology</subject><subject>Vaccination</subject><issn>1521-6616</issn><issn>1521-7035</issn><issn>1365-2567</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkk2LFDEQhoMo7of-AQ_SFxc9TFvJdJJukIVl1tXFBQ9-XEO6kmDG7vSYdI_Mvze907DgQU8pwvNWiidFyAsKJQUq3m5L7HxfMgBZQlUCpY_IKeWMriSs-eOlFoKKE3KW0hYAOGPiKTmhUgCrZXVKPl3h6Pe22GtEH_Toh1D4UOxyZcOYit9-_FHg0Pf5fq-j121nC9_3UxiMdR4zhYfi9eb77fWbZ-SJ012yz5fznHy7ef9183F19_nD7ebqboWVhHGlazSVo5a3jBtgQA00WDNwYu1a3dQGG4e1aA01rdRVaw0yDq0ztHHcOLk-JxfHvrs4_JpsGlXvE9qu08EOU1KippJJ-D_IsibW8BlkRxDjkFK0Tu2i73U8KApqdq22anatZtcKKpVd59DLpfvU9tY8RBa5GXi1ADqh7lzUAX164BqomOAsc--OnM3S9t5Gle69WuOjxVGZwf97jsu_4hkJPr_40x5s2g5TDPk7FFWJKVBf5q2YlwJkTtdA138APAiyEg</recordid><startdate>20070901</startdate><enddate>20070901</enddate><creator>Goldacker, S</creator><creator>Draeger, R</creator><creator>Warnatz, K</creator><creator>Huzly, D</creator><creator>Salzer, U</creator><creator>Thiel, J</creator><creator>Eibel, H</creator><creator>Schlesier, M</creator><creator>Peter, H.H</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20070901</creationdate><title>Active vaccination in patients with common variable immunodeficiency (CVID)</title><author>Goldacker, S ; Draeger, R ; Warnatz, K ; Huzly, D ; Salzer, U ; Thiel, J ; Eibel, H ; Schlesier, M ; Peter, H.H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-a8cd4f1e5b25d0201d09c820f63fba98dc9fc86bd1db7a4bedc250bfd19f5df73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Allergy and Immunology</topic><topic>Antibody Formation - immunology</topic><topic>B-Lymphocytes - classification</topic><topic>B-Lymphocytes - immunology</topic><topic>Biological and medical sciences</topic><topic>Common Variable Immunodeficiency - classification</topic><topic>Common Variable Immunodeficiency - immunology</topic><topic>Common Variable Immunodeficiency - therapy</topic><topic>CVID</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Humans</topic><topic>IgM memory B cells</topic><topic>Immunoglobulin G - blood</topic><topic>Immunoglobulin M - blood</topic><topic>Immunologic Memory</topic><topic>Lymphocyte Subsets - classification</topic><topic>Lymphocyte Subsets - immunology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Peptides - therapeutic use</topic><topic>Pneumococcal polysaccharides</topic><topic>Pneumococcal Vaccines - therapeutic use</topic><topic>Polypeptides</topic><topic>Polysaccharides - therapeutic use</topic><topic>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</topic><topic>Streptococcus pneumoniae - immunology</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goldacker, S</creatorcontrib><creatorcontrib>Draeger, R</creatorcontrib><creatorcontrib>Warnatz, K</creatorcontrib><creatorcontrib>Huzly, D</creatorcontrib><creatorcontrib>Salzer, U</creatorcontrib><creatorcontrib>Thiel, J</creatorcontrib><creatorcontrib>Eibel, H</creatorcontrib><creatorcontrib>Schlesier, M</creatorcontrib><creatorcontrib>Peter, H.H</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical Immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goldacker, S</au><au>Draeger, R</au><au>Warnatz, K</au><au>Huzly, D</au><au>Salzer, U</au><au>Thiel, J</au><au>Eibel, H</au><au>Schlesier, M</au><au>Peter, H.H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Active vaccination in patients with common variable immunodeficiency (CVID)</atitle><jtitle>Clinical Immunology</jtitle><addtitle>Clin Immunol</addtitle><date>2007-09-01</date><risdate>2007</risdate><volume>124</volume><issue>3</issue><spage>294</spage><epage>303</epage><pages>294-303</pages><issn>1521-6616</issn><eissn>1521-7035</eissn><eissn>1365-2567</eissn><coden>CLIIFY</coden><abstract>Abstract Active vaccination of CVID patients with standard vaccines has rarely been studied in depth although some patients have been shown to develop transient vaccine-specific immunity. We addressed the question whether these patients can be identified by functional classification of their B cell subsets in vitro . Twenty-one CVID patients receiving regular IgG substitution were immunized with anti-peptide and anti-polysaccharide vaccines. Humoral vaccination responses were compared to the numbers of circulating memory B cells, CD21low B cells and the capacity to produce antibodies in vitro. Our findings allow four conclusions: (1) positive vaccination responses are not contradictory to the diagnosis of CVID; they occurred against polypeptide vaccines in 23% and against polysaccharide antigens in 18% of all vaccinations. (2) Class-switched antibody responses occur preferentially in patients of CVID group II. (3) A normal percentage of IgM memory B cells is necessary but not sufficient for a vaccination response to polysaccharide antigens. (4) Active vaccination in addition to IgG replacement therapy should be performed in patients of CVID type II — especially in case of vaccines for which passive protection cannot be guaranteed.</abstract><cop>San Diego, CA</cop><pub>Elsevier Inc</pub><pmid>17602874</pmid><doi>10.1016/j.clim.2007.04.011</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1521-6616 |
| ispartof | Clinical Immunology, 2007-09, Vol.124 (3), p.294-303 |
| issn | 1521-6616 1521-7035 1365-2567 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68172707 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Elsevier ScienceDirect Journals; Wiley Online Library Free Content; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; IngentaConnect Free/Open Access Journals; PubMed Central |
| subjects | Adult Aged Allergy and Immunology Antibody Formation - immunology B-Lymphocytes - classification B-Lymphocytes - immunology Biological and medical sciences Common Variable Immunodeficiency - classification Common Variable Immunodeficiency - immunology Common Variable Immunodeficiency - therapy CVID Female Fundamental and applied biological sciences. Psychology Fundamental immunology Humans IgM memory B cells Immunoglobulin G - blood Immunoglobulin M - blood Immunologic Memory Lymphocyte Subsets - classification Lymphocyte Subsets - immunology Male Medical sciences Middle Aged Peptides - therapeutic use Pneumococcal polysaccharides Pneumococcal Vaccines - therapeutic use Polypeptides Polysaccharides - therapeutic use Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis Streptococcus pneumoniae - immunology Vaccination |
| title | Active vaccination in patients with common variable immunodeficiency (CVID) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T10%3A46%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Active%20vaccination%20in%20patients%20with%20common%20variable%20immunodeficiency%20(CVID)&rft.jtitle=Clinical%20Immunology&rft.au=Goldacker,%20S&rft.date=2007-09-01&rft.volume=124&rft.issue=3&rft.spage=294&rft.epage=303&rft.pages=294-303&rft.issn=1521-6616&rft.eissn=1521-7035&rft.coden=CLIIFY&rft_id=info:doi/10.1016/j.clim.2007.04.011&rft_dat=%3Cproquest_cross%3E68172707%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20352957&rft_id=info:pmid/17602874&rft_els_id=1_s2_0_S1521661607011801&rfr_iscdi=true |